{"id":"cilta-cel-oos-therapy","safety":{"commonSideEffects":[{"rate":"30-40%","effect":"Cytokine release syndrome"},{"rate":"20-30%","effect":"Neutropenia"},{"rate":"20-30%","effect":"Anemia"},{"rate":"10-20%","effect":"Thrombocytopenia"}]},"_chembl":{"chemblId":"CHEMBL509173","moleculeType":"Small molecule","molecularWeight":"976.13"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Cilta-cel is a chimeric antigen receptor T-cell therapy that selectively targets and eliminates cancer cells.","oneSentence":"Chimeric antigen receptor T-cell therapy","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:26:47.429Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory multiple myeloma"}]},"trialDetails":[{"nctId":"NCT05346835","phase":"","title":"Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma","status":"AVAILABLE","sponsor":"Janssen Scientific Affairs, LLC","startDate":"","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT05347485","phase":"PHASE2","title":"A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2022-05-13","conditions":"Multiple Myeloma","enrollment":86}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["JNJ-68284528"],"phase":"phase_2","status":"active","brandName":"Cilta-cel OOS Therapy","genericName":"Cilta-cel OOS Therapy","companyName":"Janssen Scientific Affairs, LLC","companyId":"janssen-scientific-affairs-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Chimeric antigen receptor T-cell therapy Used for Relapsed or refractory multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}